A Randomized Phase II Study Evaluating Efficacy and Safety of 2nd or 3rd Line Treatment by Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms MAPS2
- 25 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 16 Jan 2019 Status changed from active, no longer recruiting to completed, according to the results published in the Lancet Oncology
- 16 Jan 2019 Primary endpoint (Disease Control rate assessed by CT scan) has been met, according to the results published in the Lancet Oncology